Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FREE-study
NL-OMON59122Phase 4Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab and infliximab in Crohn's disease and autoimmune colitis (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Cumulative incidence of out-of-range fecal calprotectin results at 48 weeks. Started Sep 2024; status: recruiting.
02
Drugs
adalimumabinfliximab
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON59122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59122.